Literature DB >> 34511945

Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision.

Ying Wang1, Xinping Zhang1, Xuemei Wang1, Xiaoquan Lai2.   

Abstract

PURPOSE: Empirical antibiotic therapy should follow the local bacterial susceptibility, and the breakpoints revisions of the antimicrobial susceptibility testing can reflect the changes in the antimicrobial susceptibility of bacteria. This study aimed to analyze whether the changes in the antimicrobial susceptibility to antibiotics caused by the breakpoint revision will affect the empirical antibiotic therapy and its appropriateness. PATIENTS AND METHODS: A retrospective study was conducted among 831 hospitalized patients infected by Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from April 10, 2018, to April 11, 2020. We evaluated the appropriateness of empirical therapy based on the antimicrobial susceptibility testing results. The rate of empirical use and appropriateness of fluoroquinolones was calculated, and logistic regression was used to analyze influencing factors of empirical use of fluoroquinolones.
RESULTS: The susceptibility rate of the three bacteria to levofloxacin (50.78% vs 32.06%) and ciprofloxacin (48.45% vs 21.90%) was decreased (P<0.001), while the resistance rate to levofloxacin (45.74% vs 58.73%) and ciprofloxacin (46.90% vs 66.67%) was increased (P<0.001) after the breakpoints revision. The empirical usage rate of fluoroquinolones in patients infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa was 20.94%, which was influenced by the breakpoint revision (P=0.022), age (P=0.007), and the department (P=0.006); the appropriateness rate was 28.74%, affected by the pathogenic bacteria (P=0.001) and multidrug-resistant microorganism (P=0.001), department (P=0.024), and the length of stay before the empirical therapy (P=0.016).
CONCLUSION: The susceptibility of bacteria to antibiotics has changed significantly after the breakpoint revision while the clinicians' empirical therapy failure to change accordingly, which results in the decrease of the appropriateness of empirical use. It is enlightened that we should conduct more research to evaluate the rational use of antibiotics from the laboratory perspective and carry out interventions such as education and supervision to strengthen the collaboration between the microbiology laboratories and clinicians to improve the empirical antibiotic therapy and slow down the antimicrobial resistance.
© 2021 Wang et al.

Entities:  

Keywords:  antimicrobial resistance; antimicrobial susceptibility testing; appropriateness; breakpoint revision; empirical antibiotic therapy; fluoroquinolones

Year:  2021        PMID: 34511945      PMCID: PMC8418362          DOI: 10.2147/IDR.S329477

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


  39 in total

1.  Suitability of initial antibiotic therapy for the treatment of bloodstream infections and the potential role of antibiotic management teams in improving it.

Authors:  S Diamantis; C Rioux; C Bonnal; É Farfour; E Papy; A Andremont; P Yeni; É Bouvet; J-C Lucet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-02       Impact factor: 3.267

2.  Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.

Authors:  Emily L Heil; J Kristie Johnson
Journal:  J Clin Microbiol       Date:  2016-01-20       Impact factor: 5.948

3.  Effect of initial empiric antibiotic therapy combined with control of the infection focus on the prognosis of patients with secondary peritonitis.

Authors:  Estela Membrilla-Fernández; Juan J Sancho-Insenser; Meritxell Girvent-Montllor; Francisco Álvarez-Lerma; Antonio Sitges-Serra
Journal:  Surg Infect (Larchmt)       Date:  2014-12       Impact factor: 2.150

Review 4.  The challenge of antimicrobial resistance: What economics can contribute.

Authors:  Laurence S J Roope; Richard D Smith; Koen B Pouwels; James Buchanan; Lucy Abel; Peter Eibich; Christopher C Butler; Pui San Tan; A Sarah Walker; Julie V Robotham; Sarah Wordsworth
Journal:  Science       Date:  2019-04-05       Impact factor: 47.728

5.  Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.

Authors:  Donald I Hsu; Mark P Okamoto; Rekha Murthy; Annie Wong-Beringer
Journal:  J Antimicrob Chemother       Date:  2005-02-22       Impact factor: 5.790

6.  Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.

Authors:  Po-Yu Liu; Zhi-Yuan Shi; Kwong-Chung Tung; Ching-Lin Shyu; Kun-Wei Chan; Jai-Wen Liu; Zong-Yen Wu; Chih-Chuan Kao; Yi-Ching Huang; Chin-Fu Lin
Journal:  J Infect Dev Ctries       Date:  2014-03-13       Impact factor: 0.968

7.  Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.

Authors:  Hande Arslan; Ozlem Kurt Azap; Onder Ergönül; Funda Timurkaynak
Journal:  J Antimicrob Chemother       Date:  2005-09-20       Impact factor: 5.790

8.  Adoption of the New CLSI Fluoroquinolone Breakpoints for Enterobacteriaceae.

Authors:  Yiu-Wai Chu; Herman Tse; Dominic Tsang
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

Review 9.  The newer fluoroquinolones.

Authors:  Maureen K Bolon
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

10.  Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department.

Authors:  Sebastian Bischoff; Thomas Walter; Marlis Gerigk; Matthias Ebert; Roger Vogelmann
Journal:  BMC Infect Dis       Date:  2018-01-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.